Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 51Colorectal Neoplasms 44Carcinoma, Hepatocellular 36Rectal Neoplasms 26Lung Neoplasms 23Colonic Neoplasms 22Neoplasm Metastasis 18Esophageal Neoplasms 18Cholangiocarcinoma 15Breast Neoplasms 13Stomach Neoplasms 12Glioma 11Ovarian Neoplasms 10Melanoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Renal Cell 9Anus Neoplasms 9Sarcoma 8Uterine Cervical Neoplasms 7Prostatic Neoplasms 7Medulloblastoma 7Lymphoma, Non-Hodgkin 7Ependymoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Wilms Tumor 6Rhabdomyosarcoma 6Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6

Interventions

fludarabine 3Vaccines 3Radiotherapy 3Papillomavirus Vaccines 3Nivolumab 3Cyclophosphamide 3pembrolizumab 2entinostat 2aldesleukin 2aflibercept 2Trastuzumab 2Surveys and Questionnaires 2Specimen Handling 2Radiation 2Observation 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2Adoptive Transfer 2trastuzumab deruxtecan 1tivozanib 1tipifarnib 1rocakinogene sifuplasmid 1oncogene protein E7, Human papillomavirus type 16 1nanocis 1durvalumab 1bintrafusp alfa protein, human 1atezolizumab 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Magnetic Resonance Spectroscopy × Gastrointestinal × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03403465 2026-02-27

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

Duke University

Phase 2 Active not recruiting
90 enrolled
GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡